Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Antroquinonol||Hocena||mTOR Inhibitor 51||Hocena (antroquinonol) is derived from the fungus, Antrodia camphorata, and has been reported to have antitumor effects against various cancer cells through inhibition of mTOR (PMID: 21185843).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Antroquinonol||Phase I||Actionable||In a Phase I trial, antroquinonol (Hocena) demonstrated safety and preliminary efficacy in metastatic NSCLC patients previously treated with two prior chemotherapy regimens (PMID: 26807250).||26807250|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03310632||Phase Ib/II||Antroquinonol||Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer||Recruiting|
|NCT02047344||Phase II||Antroquinonol||Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC||Completed|